Patientrack becomes Alcidion following acquisition

Technology company Patientrack, which provides vital signs and electronic observations technology to NHS hospitals, will now be known as Alcidion.

Patientrack had been acquired by Alcidion Group in 2018. The company’s product – also called Patientrack – will still be available to NHS hospitals.

Hospitals have recorded gains in patient safety by using the technology – including reductions in cardiac arrests, mortality, lengths of stay, and admissions to intensive care. They have also innovated with the Patientrack technology to tackle conditions such as acute kidney injury and sepsis.

Whilst the Patientrack product will remain fully supported with the same UK team, the company has now been formally rebranded as Alcidion, to reflect its wider offering of cutting-edge technology to the NHS, designed to transform healthcare.

Donald Kennedy, UK general manger, Alcidion, said: “We are building on a remarkable legacy of collaboration with the NHS that has delivered a big impact on patient safety.

“As Alcidion, we have the ability to take this to the next level, and to offer the NHS a much wider set of digital tools. These have been designed to not only support the next generation of patient safety, but to streamline patient journeys, increase operational efficiency, inform clinical decision making and help hospitals to understand their data.

“We are already doing all of this with early NHS pioneers, and so it is only fitting that we adopt our new identity that reflects our even more compelling offer to the NHS.”

Dartford and Gravesham NHS Trust became the first UK organisation to procure the full Alcidion product suite in a five-year partnership announced earlier in 2019. The Trust is deploying a health technology platform that will transform patient safety and clinical efficiency for its hospitals and its local healthcare system partners and will help the trust realise its mission to become a self-made digital exemplar.

Alcidion provides solutions spanning predictive analytics, patient flow, clinical messaging, integration support, and clinical decision making. The Patientrack product will continue to perform its electronic observations, patient assessments and early warning role, as part of an integrated offering with other Alcidion products. This includes the Miya platform, which provides decision intelligence software that consolidates real-time data from disparate healthcare IT systems and pushes decision intelligence and guidance to users via mobile devices.

The Miya platform is cloud based with analytics tools to help professionals manage clinical workflows and reduce avoidable injury by providing logistical tools.

Smartpage, the company’s clinical messaging system is used in hospitals with the aim to improve communication and safety in the clinical environment.

Kate Quirke, managing director of Alcidion, said: “This is about transforming healthcare together, by empowering doctors and nurses to deliver the best possible outcomes for their patients. We are already working with the NHS to use technology in a way that delivers insights to clinicians so they can prevent and intervene.

“Healthcare professionals need to understand how their patients are progressing and need to have information about their current status and potential risk. Alcidion has rapidly developed in the last 12 months in meeting these challenges, with acquisitions allowing us to grow into a leading informatics company helping healthcare providers throughout the world.

“People in the NHS have come to know Patientrack as an important innovator in the patient safety arena, and we now look forward to developing that innovation to a growing number of areas, as we continue to partner with one of the most respected health institutions in the world to deliver the best for its patients.”


'Patientrack becomes Alcidion following acquisition' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2019 Rapid Life Sciences Ltd, a Rapid News Group Company. All Rights Reserved.

Privacy policy

Terms and conditions